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Introduction 
Spray-dried lactose is one of the most used filler-binders in direct compaction of tablets [1]. 
Spray-dried lactose is produced by spray-drying a suspension of α-lactose monohydrate 
crystals   in a saturated aqueous solution of lactoses. The resulting product is composed of 
spherical particles, containing 80-85% crystals of α-lactose monohydrate (primary 
particles) and 15-20% amorphous lactose [2].  
The compactibility of two commercial spray-dried lactoses, Pharmatose® DCL 11 
(DCL11), prepared from α-lactose monohydrate with a median primary particle size of 34 
µm and a new product, Pharmatose® DCL 14 (DCL14), prepared from 20 µm primary 
particles, were investigated. Both products are market from DMV International (Veghel, 
The Netherlands). 
Methods 
Flat tablets (500 mg weight; 13 mm diameter) were prepared from pure spray-dried lactose 
or from blends of lactose with 0.5% magnesium stearate on a programmable compaction 
simulator (ESH testing, Brierley Hill, UK), applying different compression forces (range 
10-25 kN). The compression rates were 3 and 300 mm/s, reflecting a slow lab machine and 
high speed rotary press, respectively.  
Tablet dimensions, weights and crushing strength were measured, after storage for at least 
18 h at 20°C and 30% relative humidity (R.H.); porosity and tensile strength were 
calculated..  
Tablet formulations were prepared by mixing DCL11 or DCL14 (90.3%) with theophylline 
monohydrate (5%), croscarmellose sodium (Primellose®) (4%), colloidal silica (Aerosil®  
200) (0.2%) and magnesium stearate (0.5%) on the compaction simulator at 20 kN and 300 
mm/s. The crushing strength, the disintegration time and the dissolution rate of 




The binding properties of DCL14 are significantly better than those of DCL11, because the 
small primary particles of DCL14 have larger surface area as well as the larger coated 
surface with amorphous lactose than those od DCL11. 
Both lactoses have relatively low compaction speed sensitivity and  rather low lubricant  
sensitivity. The compaction speed sensitivity is largest for DCL14, but even at high speed, 
the crushing strength of the tablets is significantly higher than for tablets prepared from 
DCL11. The compaction properties of the lubricated spray-dried lactoses are excellent and 
that the best performance is found for DCL14. 
Comparison of theophylline monohydrate tablets with DCL11 and DCL14 as filler-binder, 
respectively, compressed at 20 kN, shows that the tablets containing DCL14 gave the 
strongest and, as a consequence, the somewhat longer disintegration time.  
The dissolution rate of theophylline monohydrate for both formulations is very fast: after 8 
minutes, the dissolution is complete. 
Conclusions 
Both spray-dried lactose investigated, Pharmatose® DCL 11 and Pharmatose® DCL 14, 
have rather low lubricant sensitivity and low compaction speed sensitivity in the range 3-
300 mm/s.  
However, the new product, Pharmatose® DCL 14 has a better compactibility than the 
existing product DCL11, even if compressed at high speed and even after lubrication. This 
effect is caused by the smaller primary particle size of α-lactose monohydrate in the spray-
dried particles of DCL14.  
Example of formulations show that tablets with good overall properties can be prepared 
using Pharmatose® DCL 14.  
So, the compaction properties of spray-dried lactose could be improved by the introduction 
of a spray-dried lactose containing smaller primary particles 
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